Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lilly, Incyte Phase 3 Study of Covid-19 Drug Didn't Meet Primary Endpoint

04/08/2021 | 05:29am EDT

By Dave Sebastian

Eli Lilly & Co. and Incyte Corp. said a Phase 3 study evaluating a study of a drug applied to hospitalized Covid-19 patients didn't meet statistical significance on the primary endpoint.

The companies said they defined the primary endpoint as a difference in the proportion of participants progressing to the first occurrence of noninvasive ventilation, invasive mechanical ventilation or death by Day 28. Patients treated with baricitinib were 2.7% less likely than those receiving standard care to progress to ventilation or death, the companies said Thursday.

The treatment with baricitinib in addition to the standard care--which included 79% receiving corticosteroids and 19% receiving remdesivir, with some receiving both--led to a statistically significant reduction in death from any cause by 38% by Day 28, the companies said.

"While [the study] COV-BARRIER did not hit the primary endpoint based on stages of disease progression, the data show that baricitinib meaningfully reduced the risk of mortality above and beyond the recommended standard of care, without additional safety risks," said co-primary investigator E. Wesley Ely, professor of medicine at the Vanderbilt University Medical Center.

The study of 1,525 patients began in June 2020 and enrolled hospitalized patients who didn't require supplemental oxygen, the companies said.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

04-08-21 0729ET

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -1.34% 181.95 Delayed Quote.9.27%
INCYTE CORPORATION -0.36% 79.66 Delayed Quote.-8.07%
All news about ELI LILLY AND COMPANY
07:25aELI LILLY AND  : Lilly Modifies Purchase Deal With US Government on COVID-19 Ant..
MT
07:16aEli Lilly to focus on selling COVID-19 antibody drug combination
RE
06:54aEli Lilly ends supply agreement with U.S. govt for COVID-19 antibody drug
RE
05:12aEli Lilly Changes U.S. Supply Agreement for Covid-19 Drugs
DJ
04/10ELI LILLY AND  : Exclusive Speaker Interview with Achim Kless, Pain Genetics Lea..
AQ
04/09SECTOR UPDATE : Health Care Stocks Continue to Gain Strength Ahead of Closing Be..
MT
04/08INCYTE  : Eli Lilly's arthritis drug fails to prevent mechanical ventilation in ..
RE
04/08ELI LILLY AND  : Lilly, Incyte COVID-19 Drug Fails To Meet Primary Endpoint
MT
04/08INCYTE  : Eli Lilly's arthritis drug fails to meet main goal of late-stage COVID..
RE
04/08ELI LILLY AND  : Lilly and Incyte announce results from the Phase 3 COV-BARRIER ..
PR
More news
Financials (USD)
Sales 2021 27 847 M - -
Net income 2021 7 073 M - -
Net Debt 2021 11 626 M - -
P/E ratio 2021 23,4x
Yield 2021 1,81%
Capitalization 168 B 168 B -
EV / Sales 2021 6,44x
EV / Sales 2022 6,26x
Nbr of Employees 35 000
Free-Float 99,5%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 215,49 $
Last Close Price 184,49 $
Spread / Highest target 38,8%
Spread / Average Target 16,8%
Spread / Lowest Target -7,85%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Senior VP, Chief Information & Digital Officer
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY9.27%167 700
JOHNSON & JOHNSON2.46%424 524
ROCHE HOLDING AG0.21%288 043
PFIZER, INC.-0.57%204 161
NOVARTIS AG-3.29%197 172
MERCK & CO., INC.-6.71%193 164